Cognition Therapeutics

About COGNITION THERAPEUTICS INC

Cognition Therapeutics Inc is a biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies. The company's lead product candidate, Zervimesine (CT1812), is an oral, once-daily small molecule designed to rescue neuronal trafficking deficits and protect neurons by targeting toxic proteins that cause cognitive decline. Cognition Therapeutics aims to slow the progression of central nervous system disorders by maintaining normal neuronal function and addressing the underlying mechanisms of neurodegeneration.